Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrolizumab Autoinjector Usability in Healthy Subjects
NCT02629744Phase 1Completed
- Sponsor
- Genentech
- Start
- Dec 2015
- Primary completion
- Jun 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Etrolizumab in ulcerative colitis (UC) and Crohn's disease, sponsored by Genentech. Primary endpoint: Percentage of Participants Experiencing Greater Than Mild Pain Immediately Following Injection at Time 0 Minute by 7-point Verbal Descriptive Scale (VDS-7). Started Dec 2015; status: completed.
02
Drugs
Etrolizumab
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT02629744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02629744.